1. Search Result
Search Result
Results for "

SRC-1

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

4

Peptides

4

Recombinant Proteins

1

Isotope-Labeled Compounds

4

Antibodies

4

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-123402
    GSK3987
    1 Publications Verification

    LXR Metabolic Disease
    GSK3987 is a pan LXRα/β agonist with EC50s of 50 nM, 40 nM for LXRα-SRC1 and LXRβ-SRC1, respectively. GSK3987 increases the expression of ABCA1 and SREBP-1c. GSK3987 induces cellular cholesterol efflux and triglyceride accumulation [1].
    GSK3987
  • HY-117819

    ROR Inflammation/Immunology
    TMP920 is a highly potent and selective RORγt antagonist. TMP920 inhibits RORγt binding to the SRC1 peptide with an IC50 of 0.03 μM [1].
    TMP920
  • HY-RS29186

    SRC-1

    Small Interfering RNA (siRNA) Others
    Ncoa1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ncoa1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
    Ncoa1 Rat Pre-designed siRNA Set A
    Ncoa1 Rat Pre-designed siRNA Set A
  • HY-RS22672

    SRC1; NRC-1; SRC-1; SRC-a; KAT13A; NCoA-1; mNRC-1; bHLHe74

    Small Interfering RNA (siRNA) Others

    Ncoa1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ncoa1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ncoa1 Mouse Pre-designed siRNA Set A
    Ncoa1 Mouse Pre-designed siRNA Set A
  • HY-RS09089

    SRC1; KAT13A; RIP160; F-SRC-1; bHLHe42; bHLHe74

    Small Interfering RNA (siRNA) Others

    NCOA1 Human Pre-designed siRNA Set A contains three designed siRNAs for NCOA1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    NCOA1 Human Pre-designed siRNA Set A
    NCOA1 Human Pre-designed siRNA Set A
  • HY-RS13749

    ASV; SRC1; THC6; c-SRC; p60-SRC

    Small Interfering RNA (siRNA) Others

    SRC Human Pre-designed siRNA Set A contains three designed siRNAs for SRC gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    SRC Human Pre-designed siRNA Set A
    SRC Human Pre-designed siRNA Set A
  • HY-P5464

    Estrogen Receptor/ERR Others
    SRC-1 NR box peptide is a biological active peptide (This peptide is a 14-amino acid fragment from the steroid receptor cofactor SRC-1 NR II). SRC-1 NR box peptide can be used to study the regulatory mechanisms of estrogen receptor ligands [1].
    SRC-1 NR box peptide
  • HY-P5458

    Mineralocorticoid Receptor Others
    SRC-1 (686-700) is a biological active peptide. (This peptide is amino acids 686 to 700 fragment containing the second LXXLL motif, derived from NR box II of steroid receptor coactivator (SRC1). Coactivator proteins interact with nuclear receptors in a ligand-dependent manner and augment transcription.)
    SRC-1 (686-700)
  • HY-P5559

    PROTACs Cancer
    ND1-YL2 is a PROTAC that selectively degrades SRC-1 via the N-degron pathway. ND1-YL2 significantly inhibits cancer invasion and migration in vitro and in vivo. ND1-YL2 can be used in cancer research [1].
    ND1-YL2
  • HY-139562

    FXR Metabolic Disease
    BMS-986318 is a potent nonbile acid FXR agonist with EC50s of 53 and 350 nM in the FXR Gal4 and SRC-1 recruitment assays, respectively. BMS-986318 has a suitable ADME profile, and demonstrates efficacy in the mouse bile duct ligation model of liver cholestasis and fibrosis.BMS-986318 can be used for the research of nonalcoholic steatohepatitis [1].
    BMS-986318
  • HY-15606
    Tanaproget
    1 Publications Verification

    NSP-989

    Progesterone Receptor Endocrinology
    Tanaproget is an orally effective, selective nonsteroidal progesterone receptor (PR) agonist targeting human PR with an IC50 of 1.7 nM. Tanaproget promotes the interaction between PR receptors and coactivators (such as SRC-1), thereby inhibiting the secretion of matrix metalloproteinases (MMP-3/MMP-7) and reducing endometrial tissue invasion and angiogenesis. Tanaproget can be used for contraception and endometriosis inhibition research [1] .
    Tanaproget
  • HY-116028

    15-Deoxy-Δ12,14-PGD2

    Endogenous Metabolite Prostaglandin Receptor PPAR Src Cardiovascular Disease
    15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2), a metabolite of PGD2 (HY-101988), is an agonist of prostaglandin receptor 2 (DP2). 15-deoxy-Δ12,14-Prostaglandin D2 binds to DP2 (Ki=50 nM) and induces eosinophil activation (EC50=8 nM). 15-deoxy-Δ12,14-Prostaglandin D2 also stimulates the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), inducing PPARγ-mediated transcription. 15-deoxy-Δ12,14-Prostaglandin D2 (15-Deoxy-Δ12,14-PGD2) is cytotoxic to L1210 murine leukemia cells (IC50=0.3 μg/ml) and inhibits ADP-induced platelet aggregation (IC50=320 ng/mL).
    15-deoxy-Δ12,14-Prostaglandin D2
  • HY-18507A

    RET Src Ribosomal S6 Kinase (RSK) Raf Cancer
    AD57 hydrochloride is an orally active multikinase inhibitor, inhibits RET, BRAF, S6K and Src .
    AD57 hydrochloride
  • HY-116699

    PPAR Neurological Disease Metabolic Disease Inflammation/Immunology
    CP-868388 free base is a potent, selective and orally active PPARα agonist with a Ki value of 10.8 nM. CP-868388 free base has little or no affinity for PPARβ (Ki of 3.47 μM) and PPARγ. CP-868388 free base has hypolipidemic and anti-inflammatory actions [1].
    CP-868388 free base
  • HY-P3773

    Src Cancer
    p60c-src substrate II is an efficient pentapeptide substrate for the tyrosine kinase pp60c-src .
    p60c-src substrate II
  • HY-156914

    IGF-1R Src Cancer
    IGF-1R/SRC-IN-1 (Compound 3b) is an inhibitor for IGF-1R (IC50 is 63 μM) and SRC .
    IGF-1R/SRC-IN-1
  • HY-153833

    KVA-E-23A

    Gap Junction Protein Cancer
    PDS-0330 is a specific and potent Claudin-1 inhibitor. PDS-0330 interferes with claudin-1/Src association and inhibits colorectal cancer (CRC) progression and metastasis [1].
    PDS-0330
  • HY-169670

    Pim CDK GSK-3 Src Cancer
    Protein kinase inhibitor 13 (Compound I-90) is the inhibitor for protein kinase that exhibits inhibitory effects on kinases such as PIM-1, CDK-2, GSK-3 and SRC .
    Protein kinase inhibitor 13
  • HY-112096
    eCF506
    3 Publications Verification

    NXP900

    Src Cancer
    eCF506 (NXP900) is a highly potent and orally active YES1/SRC kinase inhibitor with an IC50 of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer [1].
    eCF506
  • HY-112096S

    NXP900-d5

    Src Isotope-Labeled Compounds Cancer
    eCF506-d5 (NXP900-d5) is deuterated labeled eCF506 (HY-112096). eCF506 is a highly potent and orally active YES1/SRC kinase inhibitor with an IC50 of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer [1] .
    eCF506-d5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: